Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | SLC13A5 | Q86YT5 | 9/20 | 0.46 |
| ▸ | ACLY | P53396 | 3/20 | 0.41 |
| ▸ | CPT2 | P23786 | 1/20 | 0.41 |
| ▸ | HMGCR | P04035 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14818896 | 1.00 | ALDH1A1 (0.67) | ALDH1A1SLC13A5ACLYCPT2HMGCR | |
| Citric Acid SCHEMBL2636987 | 0.84 | ALDH1A1 (0.83) | ALDH1A1SLC13A5ACLYCPT2HMGCR | |
| Citric Acid SCHEMBL426935 | 0.84 | ALDH1A1 (0.83) | ALDH1A1SLC13A5ACLYCPT2HMGCR | |
| Citric Acid SCHEMBL9299044 | 0.84 | ALDH1A1 (0.94) | ALDH1A1SLC13A5ACLYCPT2HMGCR | |
| Citric Acid SCHEMBL227914 | 0.84 | ALDH1A1 (0.94) | ALDH1A1SLC13A5ACLYCPT2HMGCR | |
| Citric Acid SCHEMBL664207 | 0.84 | ALDH1A1 (0.94) | ALDH1A1SLC13A5ACLYCPT2HMGCR | |
| Citric Acid SCHEMBL29629071 | 0.84 | ALDH1A1 (0.94) | ALDH1A1SLC13A5ACLYCPT2HMGCR | |
| Citric Acid SCHEMBL28100234 | 0.82 | ALDH1A1 (0.79) | ALDH1A1SLC13A5ACLYCPT2HMGCR | |
| Citric Acid SCHEMBL5173630 | 0.81 | ALDH1A1 (0.88) | ALDH1A1SLC13A5ACLYCPT2HMGCR | |
| Citric Acid SCHEMBL5425793 | 0.81 | ALDH1A1 (0.88) | ALDH1A1SLC13A5ACLYCPT2HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180179499-A1 | BIOBASED PRODUCTION OF FUNCTIONALIZED ALPHA-SUBSTITUTED ACRYLATES AND C4-DICARBOXYLATES | LCY BIOSCIENCES INC. (CA) | 2018-06-28 | — | — | US | claimed |
| EP-3303375-A1 | BIOBASED PRODUCTION OF FUNCTIONALIZED ALPHA-SUBSTITUTED ACRYLATES AND C4-DICARBOXYLATES | BioAmber Inc. (US) | 2018-04-11 | — | — | EP | claimed |
| WO-2016196962-A1 | BIOBASED PRODUCTION OF FUNCTIONALIZED ALPHA-SUBSTITUTED ACRYLATES AND C4-DICARBOXYLATES | BIOAMBER INC. (US) | 2016-12-08 | — | — | WO | claimed |
| EP-4593888-A1 | CROSSLINKED RADIOPAQUE NETWORKS FOR MEDICAL APPLICATIONS | Boston Scientific Scimed Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20240123095-A1 | CROSSLINKED RADIOPAQUE NETWORKS FOR MEDICAL APPLICATIONS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2024-04-18 | — | — | US | disclosed |
| WO-2024073271-A1 | CROSSLINKED RADIOPAQUE NETWORKS FOR MEDICAL APPLICATIONS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20180179499-A1 | BIOBASED PRODUCTION OF FUNCTIONALIZED ALPHA-SUBSTITUTED ACRYLATES AND C4-DICARBOXYLATES | LCY BIOSCIENCES INC. (CA) | 2018-06-28 | — | — | US | disclosed |
| EP-3303375-A1 | BIOBASED PRODUCTION OF FUNCTIONALIZED ALPHA-SUBSTITUTED ACRYLATES AND C4-DICARBOXYLATES | BioAmber Inc. (US) | 2018-04-11 | — | — | EP | disclosed |
| CN-106660953-A | High heat monomers and methods of use thereof | 沙特基础工业全球技术有限公司 | 2017-05-10 | — | — | CN | disclosed |
| WO-2016196962-A1 | BIOBASED PRODUCTION OF FUNCTIONALIZED ALPHA-SUBSTITUTED ACRYLATES AND C4-DICARBOXYLATES | BIOAMBER INC. (US) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240123095-A1 | CROSSLINKED RADIOPAQUE NETWORKS FOR MEDICAL APPLICATIONS | PAICS, RAD54L, RAD18 | ALDH1A1 650/4885SLC13A5 2743/4885ACLY 2427/4885 |
| US-20180179499-A1 | BIOBASED PRODUCTION OF FUNCTIONALIZED ALPHA-SUBSTITUTED ACRYLATES AND C4-DICARBOXYLATES | COASY, ADSL, ALAD | ALDH1A1 157/4885SLC13A5 2292/4885ACLY 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.